Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
BACKGROUND
Parkinson disease (PD) patients present urinary symptoms during the course of the disease, very often suggestive of overactive bladder and sustained by neurogenic detrusor overactivity. These symptoms cause a severe lowering of quality of life determining social withdrawal and they need to be early diagnosed to restore social interaction and prevent urinary tract complications. Today overactive bladder diagnosis is easier, thanks to the availability of new investigative tools, particularly voiding questionnaires. The aim of the present study was to evaluate the reliability of the Overactive Bladder screener (OAB screener/OAB-questionnaire), a new voiding questionnaire specifically developed for the overactive bladder diagnosis in PD subjects suffering from overactive bladder symptoms. Clinical data obtained by the questionnaire were compared with urodynamic outcomes, at basal conditions and after antimuscarinic treatment, to better explorate the questionnaire reliability.


METHODS
Forty PD patients have been enrolled in the protocol, and submitted to the OAB screener, voiding diary and urodynamic investigation before and after antimuscarinic treatment. OAB-score and urodynamic parameters were statistically analyzed and compared.


RESULTS
The OAB-q well correlated with voiding diary and urodynamic data of Parkinson subjects either at baseline or after the antimuscarinic treatment. The study suggests that this clinical tool might be used for neurogenic overactive bladder diagnosis and that it seems to be a useful outcome measure for treatments of neurogenic OAB.
Palleschi
Giovanni
G
Department of Neuroscience, Neuro-Urology Unit, Polo Pontino, University of Rome La Sapienza, Latina, Italy.
Pastore
Antonio Luigi
AL
Stocchi
Fabrizio
F
Bova
Gino
G
Inghilleri
Maurizio
M
Sigala
Sandra
S
Carbone
Antonio
A
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000150:complications / Q000503:physiopathology*; D011795:Surveys and Questionnaires; D001750:Urinary Bladder, Neurogenic / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D014549:Urinary Incontinence / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D014563:Urodynamics
D018727:Muscarinic Antagonists